| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |
|
Medicine details |
|
| Medicine name | lutetium-177 oxodotreotide (Lutathera®) |
| Formulation | 370 MBq/ ml solution for infusion |
| Reference number | 2445 |
| Indication | Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours in adults |
| Company | Advanced Accelerator Applications SA |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2017 |
| NICE guidance | TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |